Pfizer Newsroom company blog
Valneva and Pfizer announce Phase 2 study for Lyme disease vaccine candidate
Saint-Herblain (France) and New York, NY, March 8, 2021 – Valneva SE (“Valneva”), a specialty vaccine company focused on prevention of diseases with major unmet needs, and Pfizer Inc. (NYSE: PFE) today announced initiation of study VLA15-221. The VLA15-221 study builds on previous positive Phase 2 studies…
- Points
- 350
- HN comments
- 248
- Submissions
- 1
- Cited by
- 0 commenters
On Hacker News
| Submitted | Title on HN | Points | Comments |
|---|---|---|---|
| Aug 26, 2021 | Valneva and Pfizer announce Phase 2 study for Lyme disease vaccine candidate by pama | 350 | 248 |
